These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 12722040)

  • 1. Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis.
    Chu P; Chao TY; Lin YF; Janckila AJ; Yam LT
    Am J Kidney Dis; 2003 May; 41(5):1052-9. PubMed ID: 12722040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tartrate-resistant acid phosphatase 5b and its correlations with other markers of bone metabolism in kidney transplant recipients and dialyzed patients.
    Małyszko J; Małyszko JS; Pawlak K; Wołczyński S; Myśliwiec M
    Adv Med Sci; 2006; 51():69-72. PubMed ID: 17357281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Tartrate-resistant acid phosphatase--TRAP 5b--as a novel marker of bone resorption in patients with irreversible renal failure treated with dialysis].
    Nowak Z; Konieczna M; Wańkowicz Z
    Pol Merkur Lekarski; 2004 Aug; 17(98):138-41. PubMed ID: 15603322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption.
    Hannon RA; Clowes JA; Eagleton AC; Al Hadari A; Eastell R; Blumsohn A
    Bone; 2004 Jan; 34(1):187-94. PubMed ID: 14751577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption.
    Halleen JM; Tiitinen SL; Ylipahkala H; Fagerlund KM; Väänänen HK
    Clin Lab; 2006; 52(9-10):499-509. PubMed ID: 17078477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide.
    Tähtelä R; Seppänen J; Laitinen K; Katajamäki A; Risteli J; Välimäki MJ
    Osteoporos Int; 2005 Sep; 16(9):1109-16. PubMed ID: 15605190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients.
    Tang C; Liu Y; Qin H; Li X; Guo W; Li J; Wang W; Qu L; Hu H; Xu C; Zheng L; Huang Y; Liu B; Gao H; Halleen JM; Liu X
    Clin Chim Acta; 2013 Nov; 426():102-7. PubMed ID: 24055775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density.
    Halleen JM; Ylipahkala H; Alatalo SL; Janckila AJ; Heikkinen JE; Suominen H; Cheng S; Väänänen HK
    Calcif Tissue Int; 2002 Jul; 71(1):20-5. PubMed ID: 12073156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum cross-linked N-terminal telopeptide of type I collagen for evaluation of renal osteodystrophy in hemodialysis patients.
    Nakashima A; Yorioka N; Mizutani T; Yamagata Z; Ueno T; Takasugi N
    Nephron Clin Pract; 2005; 99(3):c78-85. PubMed ID: 15665550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secreted tartrate-resistant acid phosphatase 5b is a Marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model.
    Rissanen JP; Suominen MI; Peng Z; Halleen JM
    Calcif Tissue Int; 2008 Feb; 82(2):108-15. PubMed ID: 18084692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development for the determination of band 5b tartrate-resistant acid phosphatase activity in serum].
    Uchida K; Nakanishi M; Yoh K
    Rinsho Byori; 2001 Jan; 49(1):51-5. PubMed ID: 11215484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tartrate-resistant acid phosphatase 5B is a specific and sensitive marker of bone resorption.
    Halleen JM
    Anticancer Res; 2003; 23(2A):1027-9. PubMed ID: 12820342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Study of tartrate resistant acid phosphatase in patients with chronic renal failure on maintenance hemodialysis].
    Maruyama Y; Arai K; Yoshida K; Motomiya Y; Kaneko Y; Hirao Y; Okajima E
    Nihon Jinzo Gakkai Shi; 1991 Apr; 33(4):397-402. PubMed ID: 1875558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum concentrations of carboxyterminal cross-linked telopeptide of type I collagen (ICTP), serum tartrate resistant acid phosphatase, and serum levels of intact parathyroid hormone in parathyroid hyperfunction.
    De la Piedra C; Díaz Martín MA; Díaz Diego EM; López Gavilanes E; González Parra E; Caramelo C; Rapado A
    Scand J Clin Lab Invest; 1994 Feb; 54(1):11-5. PubMed ID: 8171266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Study of renal osteodystrophy by bone biopsy. Age as an independent factor. Diagnostic value of bone remodeling markers].
    Jarava C; Armas JR; Palma A
    Nefrologia; 2000; 20(4):362-72. PubMed ID: 11039262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone responsiveness to parathyroid hormone is negatively associated with parathyroid hormone-lowering drug use in patients undergoing hemodialysis: a cross-sectional study.
    Tominaga N; Yonaha T; Yamanouchi M; Sumi H; Taki Y; Shibagaki Y; Shiizaki K; Yano S
    BMC Nephrol; 2021 Aug; 22(1):275. PubMed ID: 34372813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Uric Acid (UA) Negatively Affects Serum Tartrate-Resistant Acid Phosphatase 5b (TRACP 5b) Immunoassay.
    Wu ZQ; Zhang Y; Xie E; Song WJ; Yang RX; Yan CJ; Zhang BF; Xu HG
    PLoS One; 2016; 11(1):e0147554. PubMed ID: 26800211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tartrate-resistant acid phosphatase isoform 5a as an inflammation marker in end-stage renal disease.
    Janckila AJ; Lederer ED; Price BA; Yam LT
    Clin Nephrol; 2009 Apr; 71(4):387-96. PubMed ID: 19356371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis).
    Alatalo SL; Ivaska KK; Waguespack SG; Econs MJ; Väänänen HK; Halleen JM
    Clin Chem; 2004 May; 50(5):883-90. PubMed ID: 15016726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significant inverse relationship between serum undercarboxylated osteocalcin and glycemic control in maintenance hemodialysis patients.
    Okuno S; Ishimura E; Tsuboniwa N; Norimine K; Yamakawa K; Yamakawa T; Shoji S; Mori K; Nishizawa Y; Inaba M
    Osteoporos Int; 2013 Feb; 24(2):605-12. PubMed ID: 22581293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.